BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 11:33 (40 d 03:35 ago) – Posting: # 23103
Views: 433


The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!

Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,301 posts in 4,667 threads, 1,585 registered users;
online 11 (0 registered, 11 guests [including 8 identified bots]).
Forum time: Saturday 15:08 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz